Everolimus monotherapy or combined therapy in liver transplantation: Indications and results

Transplantation Proceedings

Volumn 45, Issue 5, 2013, Pages 1971-1974

  Alegre, C ^a   Jimenez C ^a   Manrique, A ^a   Abradelo, M ^a   Calvo, J ^a   Loinaz, C ^a   Garcia Sesma A ^a   Cambra, F ^a   Alvaro E ^a   Garcia M ^a   Sanabria, R ^a   Justo, I ^a   Caso, O ^a   Moreno, E ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ACNE; ADULT; AGED; ARTERY DISEASE; CANCER RECURRENCE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPENIA; DIABETES MELLITUS; DRUG ERUPTION; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MOUTH ULCER; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

AGED; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS;

EID: 84879204714     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.01.075     Document Type: Conference Paper

References (14)

1. C. Jimenez, A. Manrique, E. Marques Switching to sirolimus monotherapy for the novo tumors after liver transplantation A preliminary experience Hepatogastroenterology 58 2011 115 121
2. L. Fischer, J. Klempnauer, S. Beckebaum A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT Am J Transplant 12 2012 1855 1865
3. A.I. Sanchez-Fructoso, J.C. Ruiz, I. Perez Comparative analysis of adverse events requiring suspensión of mTOR inhibitors: everolimus vs sirolimus Transplant Proc 42 2010 3050 3052
4. K.L. Hardinger, M.J. Koch, D.C. Brennan Current and future immunosuppressive strategies in renal transplantation Pharmacotherapy 24 2004 1159 1176
5. J.M.A. Martinez, L.B. Pulido, C.B. Bellido Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation Transplant Proc 42 2010 641 643
6. F. Saliba, S. Dharancy, R. Lorho Conversion to everolimus in maintenance liver transplant patients: a multicenter retrospective analysis Liver Transpl 17 2011 905 913
7. J. Castroagudin, E. Molina, R. Romero Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with cronic renal dysfunction Liver Transpl 15 2009 1792 1797
8. S. Vitko, H. Tedesco, J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6 months safety and efficacy results of two randomized studies Am J Transplant 4 2004 625 635
9. H. Lehmkuhl, H. Ross, H.J. Eisen Everolimus (Certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure Transplant Proc 37 2005 4145 4149
10. M. Vallin, O. Guillaud, I. Morard Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients Clin Transplant 25 2011 660 669
11. P. De Simone, A. Precisi, S. Petruccelli The impact of everolimus on renal function in maintenance liver transplantation Transplant Proc 41 2009 1300 1302
12. I. Bilbao, G. Sapisochin, C. Dopazo Indications and management of everolimus after liver transplantation Transplant Proc 41 2009 2172 2176
13. M. Masetti, R. Montalti, G. Rompianesi Early withdrawal of calcineurin inhibitors and everolimus monotherapy in the novo liver transplant recipients preserves renal function Am J Transplant 10 2010 1 11
14. P. De Simone, P. Carral, A. Precisi Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function Transpl Int 22 2009 279 286